Project: A FAS ligand hexameric (APO010) and companion diagnostics in the immunotherapy of multiple myeloma

We aim to advance a new immunotherapy drug (APO010) to clinical proof of concept in the treatment of multiple myeloma (MM) by using an advanced Drug Response Predictor (DRP) analysis, based on genomic information combined with clinical tumor biology and clinical correlates in a systems biology network, as a Companion Diagnostic (CDx). APO010-sensitive patients will undergo a prospective clinical trial of APO010 exploring early efficacy signals and tolerability in a highly selected patient group

Acronym APO010-in-selected-MM (Reference Number: 10480)
Duration 01/03/2016 - 01/03/2019
Project Topic Biological Sciences / Technologies
Network Eurostars 2
Call Eurostars Cut-Off 5

Project partner

Number Name Role Country
24215 Smerud Medical Research International AS Coordinator Norway
24216 Oncology Venture ApS Partner Denmark